{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:29:34Z","timestamp":1792682974882,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00210-026-05389-4","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:15:30Z","timestamp":1778296530000},"page":"16209-16224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A real-world pharmacovigilance study of dacomitinib based on FDA adverse event reporting system (FAERS) database"],"prefix":"10.1007","volume":"399","author":[{"given":"Yuqin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4160-1875","authenticated-orcid":false,"given":"Chengjie","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-2729","authenticated-orcid":false,"given":"Maohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"5389_CR1","volume":"47","author":"AMB Abdulla","year":"2018","unstructured":"Abdulla AMB, Florian LJCP (2018) Stimulation of eryptosis by afatinib. Biochemistry BIJoECP, Pharmacology 47:1259","journal-title":"Biochemistry BIJoECP, Pharmacology"},{"issue":"13","key":"5389_CR2","first-page":"1774","volume":"28","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Haramburu F, Fourrier-R\u00e9glat A, Thiessard F, Tubert-Bitter P (2010) Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting. JSiM 28(13):1774\u20131792","journal-title":"JSiM"},{"key":"5389_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/tcrm.S137144","volume":"13","author":"A Arora","year":"2017","unstructured":"Arora A, Jalali RK, Vohora D (2017) Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs. Ther Clin Risk Manag 13:1195\u20131203. https:\/\/doi.org\/10.2147\/tcrm.S137144","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"5389_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00280-011-1793-7","volume":"69","author":"CL Bello","year":"2012","unstructured":"Bello CL, LaBadie RR, Ni G, Boutros T, McCormick C, Ndongo MN (2012) The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemother Pharmacol 69(4):991\u2013997. https:\/\/doi.org\/10.1007\/s00280-011-1793-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"5389_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5389_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3978\/j.issn.2218-6751.2014.05.01","volume":"4","author":"BA Chan","year":"2015","unstructured":"Chan BA, Hughes BG (2015) Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4(1):36\u201354. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.05.01","journal-title":"Transl Lung Cancer Res"},{"key":"5389_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107966","volume":"196","author":"M Chen","year":"2024","unstructured":"Chen M, Huang Y, Jiang S, Ke C (2024) Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: a real-world pharmacovigilance study. Lung Cancer 196:107966. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107966","journal-title":"Lung Cancer"},{"issue":"39","key":"5389_CR8","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.2217\/fon-2023-0047","volume":"19","author":"N Chintapally","year":"2023","unstructured":"Chintapally N, Nuwayhid M, Arroju V, Muddu VK, Gao P, Reddy BY, Sunkavalli C (2023) State of cancer care in India and opportunities for innovation. Future Oncol 19(39):2593\u20132606. https:\/\/doi.org\/10.2217\/fon-2023-0047","journal-title":"Future Oncol"},{"issue":"24","key":"5389_CR9","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.2217\/fon-2019-0299","volume":"15","author":"J Corral","year":"2019","unstructured":"Corral J, Mok T, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL (2019) Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. Future Oncol 15(24):2795\u20132805. https:\/\/doi.org\/10.2217\/fon-2019-0299","journal-title":"Future Oncol"},{"issue":"12","key":"5389_CR10","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00228-025-03905-8","volume":"81","author":"C Cui","year":"2025","unstructured":"Cui C, Li B, Zhang X (2025) A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for gefitinib and docetaxel. Eur J Clin Pharmacol 81(12):1795\u20131805. https:\/\/doi.org\/10.1007\/s00228-025-03905-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"5389_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09599-w","volume":"22","author":"R Du","year":"2022","unstructured":"Du R, Yang H, Zhou H, Ma L, Getu MA, Chen C, Wang T (2022) The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy. BMC Cancer 22(1):491. https:\/\/doi.org\/10.1186\/s12885-022-09599-w","journal-title":"BMC Cancer"},{"issue":"6","key":"5389_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis SJP (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5389_CR13","unstructured":"European Medicines Agency (2017) Guideline on good pharmacovigilance practices (GVP). Module IX: Signal management (Rev 1). EMA [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf"},{"key":"5389_CR14","unstructured":"Food and Drug Administration (2010) 21 CFR 312.32 IND safety reporting. Federal Register [Internet]. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2010-09-29\/html\/2010-24296.htm"},{"key":"5389_CR15","unstructured":"Food and Drug Administration (2018) FDA-Label-dacomitinib (VIZIMPRO) [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211288s000lbl.pdf"},{"key":"5389_CR16","unstructured":"Food and Drug Administration (2024a) Best practices for FDA staff in the postmarketing safety surveillance of human drug and biological products. FDA [Internet]. https:\/\/www.fda.gov\/media\/130216\/download"},{"key":"5389_CR17","unstructured":"Food and Drug Administration (2024b) FDA regional implementation guide for E2B(R3) Electronic transmission of individual case safety reports for drug and biological products. FDA [Internet]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/fda-regional-implementation-guide-e2br3-electronic-transmission-individual-case-safety-reports-drug"},{"key":"5389_CR18","unstructured":"Food and Drug Administration (2026) Drugs@FDA: FDA-Approved Drugs. Dacomitinib (VIZIMPRO) [Internet]. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=211288. Accessed 30 Apr 2026"},{"issue":"1","key":"5389_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/gim.2016.80","volume":"19","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS (2017) Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19(1):69\u201376. https:\/\/doi.org\/10.1038\/gim.2016.80","journal-title":"Genet Med"},{"issue":"5","key":"5389_CR20","first-page":"845","volume":"43","author":"AFS Galimont-Collen","year":"2007","unstructured":"Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerk J, Gelderblom HJ (2007) Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Org Chem 43(5):845\u2013851","journal-title":"Eur J Org Chem"},{"issue":"2","key":"5389_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1021\/acs.chemrestox.1c00327","volume":"35","author":"M Han","year":"2022","unstructured":"Han M, Zhang X, Ye Z, Wang J, Kong Q, Hu X, Qian J, Cai J, Hu G (2022) Effects of CYP2D6 genetic polymorphism and drug interaction on the metabolism of dacomitinib. Chem Res Toxicol 35(2):265\u2013274. https:\/\/doi.org\/10.1021\/acs.chemrestox.1c00327","journal-title":"Chem Res Toxicol"},{"key":"5389_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","volume":"61","author":"PT Harrison","year":"2020","unstructured":"Harrison PT, Vyse S, Huang PH (2020) Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol 61:167\u2013179. https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.015","journal-title":"Semin Cancer Biol"},{"issue":"7689","key":"5389_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553(7689):446\u2013454. https:\/\/doi.org\/10.1038\/nature25183","journal-title":"Nature"},{"key":"5389_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106601","volume":"84","author":"Y Hu","year":"2020","unstructured":"Hu Y, Gong J, Zhang L, Li X, Li X, Zhao B, Hai X (2020) Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. Int Immunopharmacol 84:106601. https:\/\/doi.org\/10.1016\/j.intimp.2020.106601","journal-title":"Int Immunopharmacol"},{"key":"5389_CR25","doi-asserted-by":"publisher","unstructured":"Ian Osoro N, Suhaib KP, Jamuna Rani R, Rajanandh MG\u00a0(2025) Barriers to and facilitators of healthcare professionals in ADR reporting in a tertiary care hospital in India. BMC Health Serv Res 25(1):166. https:\/\/doi.org\/10.1186\/s12913-024-12139-w","DOI":"10.1186\/s12913-024-12139-w"},{"key":"5389_CR26","unstructured":"IUPHAR\/BPS Guide to PHARMACOLOGY (2018) Dacomitinib. IUPHAR\/BPS [Internet]. https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?ligandId=7762"},{"issue":"14","key":"5389_CR27","doi-asserted-by":"publisher","first-page":"15117","DOI":"10.1002\/cam4.6184","volume":"12","author":"M Iwasaku","year":"2023","unstructured":"Iwasaku M, Uchino J, Chibana K, Tanzawa S, Yamada T, Tobino K, Uchida Y, Kijima T, Nakatomi K, Izumi M, Tamiya N, Kimura H, Fujita M, Honda R, Takumi C, Yamada T, Kaneko Y, Kiyomi F, Takayama K (2023) Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: a multicenter, phase II trial. Cancer Med 12(14):15117\u201315127. https:\/\/doi.org\/10.1002\/cam4.6184","journal-title":"Cancer Med"},{"issue":"1","key":"5389_CR28","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3727\/096504017X14913452320194","volume":"26","author":"I Kainis","year":"2018","unstructured":"Kainis I, Syrigos N, Kopitopoulou A, Gkiozos I, Filiou E, Nikolaou V, Papadavid E (2018) Erlotinib-associated rash in advanced non-small cell lung cancer: relation to clinicopathological characteristics, treatment response, and survival. Oncol Res 26(1):59\u201369. https:\/\/doi.org\/10.3727\/096504017X14913452320194","journal-title":"Oncol Res"},{"key":"5389_CR29","doi-asserted-by":"crossref","unstructured":"Katsuhiro, Masago, Kei, Irie, Shiro, Fujita, Fumiko, Imamichi, Yutaka, Research OJOIJoC, Treatment (2018) Relationship between paronychia and drug concentrations of epidermal growth factor receptor tyrosine kinase inhibitors. 95(4):251\u2013256","DOI":"10.1159\/000490177"},{"issue":"4","key":"5389_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/ijc.35193","volume":"156","author":"C Ke","year":"2025","unstructured":"Ke C, Chen M, Lin L, Huang Y (2025) Postmarketing adverse events of tamoxifen in male and female patients with breast cancer. Int J Cancer 156(4):734\u2013743. https:\/\/doi.org\/10.1002\/ijc.35193","journal-title":"Int J Cancer"},{"issue":"4","key":"5389_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.enfie.2023.12.005","volume":"35","author":"D Kohanov\u00e1","year":"2024","unstructured":"Kohanov\u00e1 D, Barton\u00ed\u010dkov\u00e1 D (2024) Barriers to reporting adverse events from the perspective of ICU nurses: a mixed-method study. Enferm Intensiva (Engl Ed) 35(4):287\u2013298. https:\/\/doi.org\/10.1016\/j.enfie.2023.12.005","journal-title":"Enferm Intensiva (Engl Ed)"},{"issue":"7","key":"5389_CR32","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","volume":"26","author":"MG Kris","year":"2015","unstructured":"Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O\u2019Connell J, Taylor I, Zhang H, Arcila ME, Goldberg Z, Janne PA (2015) Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol 26(7):1421\u20131427. https:\/\/doi.org\/10.1093\/annonc\/mdv186","journal-title":"Ann Oncol"},{"issue":"9","key":"5389_CR33","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/annonc\/mdw227","volume":"27","author":"ME Lacouture","year":"2016","unstructured":"Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty JP, Giri N, Nadanaciva S, O\u2019Connell J, Sbar E, Piperdi B, Garon EB (2016) A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol 27(9):1712\u20131718. https:\/\/doi.org\/10.1093\/annonc\/mdw227","journal-title":"Ann Oncol"},{"issue":"6","key":"5389_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27529","volume":"10","author":"Y Lin","year":"2024","unstructured":"Lin Y, Zheng X, Chen Y, Nian Q, Lin L, Chen M (2024) A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for alpelisib. Heliyon 10(6):e27529. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27529","journal-title":"Heliyon"},{"issue":"1","key":"5389_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055128","volume":"8","author":"HB Liu","year":"2013","unstructured":"Liu HB, Wu Y, Lv TF, Yao YW, Xiao YY, Yuan DM, Song Y (2013) Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS ONE 8(1):e55128. https:\/\/doi.org\/10.1371\/journal.pone.0055128","journal-title":"PLoS ONE"},{"issue":"2","key":"5389_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","volume":"81","author":"TS Mok","year":"2021","unstructured":"Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Chawla A, Rosell R, Corral J, Migliorino MR, Pluzanski A, Noonan K, Tang Y, Pastel M, Wilner KD, Wu YL (2021) Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. Drugs 81(2):257\u2013266. https:\/\/doi.org\/10.1007\/s40265-020-01441-6","journal-title":"Drugs"},{"issue":"12","key":"5389_CR37","doi-asserted-by":"publisher","first-page":"S639","DOI":"10.1016\/j.jval.2025.09.2924","volume":"28","author":"PG Nair","year":"2025","unstructured":"Nair PG, Jagadeesh S, Salma U, Bharathi B (2025) Signal Detection and Network Pharmacology Analysis of Paronychia Associated With eGFR Inhibitors. Value Health 28(12):S639. https:\/\/doi.org\/10.1016\/j.jval.2025.09.2924","journal-title":"Value Health"},{"issue":"3","key":"5389_CR38","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.21873\/anticanres.12416","volume":"38","author":"S Nasu","year":"2018","unstructured":"Nasu S, Suzuki H, Shiroyama T, Tanaka A, Iwata K, Ryota N, Ueda Y, Takata SO, Masuhiro K, Morita S, Morishita N, Okamoto N, Hirashima T (2018) Skin rash can be a useful marker for afatinib efficacy. Anticancer Res 38(3):1783\u20131788. https:\/\/doi.org\/10.21873\/anticanres.12416","journal-title":"Anticancer Res"},{"issue":"3","key":"5389_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","volume":"17","author":"AG Nicholson","year":"2022","unstructured":"Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S, Noguchi M, Papotti M, Rekhtman N, Scagliotti G, van Schil P, Sholl L, Yatabe Y, Yoshida A, Travis WD (2022) The 2021 WHO classification of lung tumors: impact of advances since 2015. J Thorac Oncol 17(3):362\u2013387. https:\/\/doi.org\/10.1016\/j.jtho.2021.11.003","journal-title":"J Thorac Oncol"},{"issue":"5","key":"5389_CR40","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1111\/cas.14384","volume":"111","author":"M Nishio","year":"2020","unstructured":"Nishio M, Kato T, Niho S, Yamamoto N, Takahashi T, Nogami N, Kaneda H, Fujita Y, Wilner K, Yoshida M, Isozaki M, Wada S, Tsuji F, Nakagawa K (2020) Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer. Cancer Sci 111(5):1724\u20131738. https:\/\/doi.org\/10.1111\/cas.14384","journal-title":"Cancer Sci"},{"issue":"5","key":"5389_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","volume":"37","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y, Tachi T, Teramachi H (2020) Comparison of Signal Detection Algorithms Based on Frequency Statistical Model for Drug-Drug Interaction Using Spontaneous Reporting Systems. Pharm Res 37(5):86. https:\/\/doi.org\/10.1007\/s11095-020-02801-3","journal-title":"Pharm Res"},{"issue":"9","key":"5389_CR42","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3760\/cma.j.cn112152-20240510-00189","volume":"46","author":"Oncology Society of Chinese Medical A","year":"2024","unstructured":"Oncology Society of Chinese Medical A (2024) [Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]. Zhonghua Zhong Liu Za Zhi 46(9):805\u2013843. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20240510-00189","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"10","key":"5389_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.70383","volume":"13","author":"K Onishi","year":"2025","unstructured":"Onishi K, Kitano T, Fujioka Y, Ota M, Onishi F, Miyake K, Tanaka H, Fujimoto N (2025) Brain Atrophy and Leukoencephalopathy Following Tarlatamab: Case Report. Respirol Case Rep 13(10):e70383. https:\/\/doi.org\/10.1002\/rcr2.70383","journal-title":"Respirol Case Rep"},{"issue":"8","key":"5389_CR44","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","volume":"4","author":"Y Oshima","year":"2018","unstructured":"Oshima Y, Tanimoto T, Yuji K, Tojo A (2018) EGFR-TKI-associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer. JAMA Oncol 4(8):1112\u20131115. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4526","journal-title":"JAMA Oncol"},{"issue":"5","key":"5389_CR45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kolbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17(5):577\u2013589. https:\/\/doi.org\/10.1016\/S1470-2045(16)30033-X","journal-title":"Lancet Oncol"},{"issue":"11","key":"5389_CR46","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ (2020) A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf 19(11):1505\u20131511. https:\/\/doi.org\/10.1080\/14740338.2020.1799975","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"5389_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","volume":"78","author":"F Petrelli","year":"2012","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S (2012) Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 78(1):8\u201315. https:\/\/doi.org\/10.1016\/j.lungcan.2012.06.009","journal-title":"Lung Cancer"},{"issue":"5\u20137","key":"5389_CR48","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.steroids.2005.02.017","volume":"70","author":"RJ Pietras","year":"2005","unstructured":"Pietras RJ, Marquez DC, Chen HW, Tsai E, Weinberg O, Fishbein M (2005) Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70(5\u20137):372\u2013381. https:\/\/doi.org\/10.1016\/j.steroids.2005.02.017","journal-title":"Steroids"},{"issue":"3","key":"5389_CR49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","volume":"118","author":"E Potter","year":"2025","unstructured":"Potter E, Reyes M, Naples J, Dal Pan G (2025) FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS. Clin Pharmacol Ther 118(3):567\u2013582. https:\/\/doi.org\/10.1002\/cpt.3701","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"5389_CR50","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.21037\/tlcr-21-989","volume":"11","author":"J Pozas","year":"2022","unstructured":"Pozas J, Albarr\u00e1n-Fern\u00e1ndez V, Gonz\u00e1lez-Campo L, Olmedo-Garc\u00eda ME, Corral de la Fuente E, Corral-Corral I, Carrasco \u00c1, Alonso-Gordoa T, Molina-Cerrillo J, Lage-Alfranca Y, G\u00f3mez-Rueda A, Garrido P (2022) Anti-Zic4 paraneoplastic cerebellar degeneration in a patient with EGFR-mutated NSCLC: a case report. Transl Lung Cancer Res 11(7):1497\u20131502. https:\/\/doi.org\/10.21037\/tlcr-21-989","journal-title":"Transl Lung Cancer Res"},{"issue":"37","key":"5389_CR51","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1080\/14796694.2024.2404762","volume":"20","author":"X Pu","year":"2024","unstructured":"Pu X, Li J, Zhang B, Zhang J, Ts KM, Nakagawa K, Rosell R, Cheng Y, Zhou X, Miglorino MR, Niho S, Lee KH, Corral J, Pluzanski A, Li J, Linke R, Pan F, Tang Y, Tan W, Wu L (2024) Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050. Future Oncol 20(37):2971\u20132982. https:\/\/doi.org\/10.1080\/14796694.2024.2404762","journal-title":"Future Oncol"},{"issue":"27","key":"5389_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029629","volume":"101","author":"F Qiao","year":"2022","unstructured":"Qiao F, Chen Q, Lu W, Fang N (2022) Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: a case report. Medicine (Baltimore) 101(27):e29629. https:\/\/doi.org\/10.1097\/MD.0000000000029629","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"5389_CR53","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1177\/10781552221139773","volume":"29","author":"X Qiu","year":"2023","unstructured":"Qiu X, Ren B, Lian Y, Fang L, Dong Z (2023) Acute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinib. J Oncol Pharm Pract 29(4):1002\u20131005. https:\/\/doi.org\/10.1177\/10781552221139773","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"5389_CR54","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/S1470-2045(14)70452-8","volume":"15","author":"SS Ramalingam","year":"2014","unstructured":"Ramalingam SS, Janne PA, Mok T, O\u2019Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O\u2019Connell J, Paz-Ares L (2014) Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol 15(12):1369\u20131378. https:\/\/doi.org\/10.1016\/S1470-2045(14)70452-8","journal-title":"Lancet Oncol"},{"issue":"4","key":"5389_CR55","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai AP, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori J, Lackner RP, Lanuti M, Lin J, Loo BW, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory KM, Hang L (2024) Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22(4):249\u2013274. https:\/\/doi.org\/10.6004\/jnccn.2204.0023","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"5389_CR56","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihimaki","year":"2014","unstructured":"Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86(1):78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020","journal-title":"Lung Cancer"},{"issue":"7","key":"5389_CR57","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1111\/bcp.13576","volume":"84","author":"L Rolfes","year":"2018","unstructured":"Rolfes L, van Hunsel F, Caster O, Taavola H, Taxis K, van Puijenbroek E (2018) Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database. Br J Clin Pharmacol 84(7):1514\u20131524. https:\/\/doi.org\/10.1111\/bcp.13576","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"5389_CR58","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/nm.2217","volume":"16","author":"MA Ryan","year":"2010","unstructured":"Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, Sengupta A, Kohler A, Liu W, Gunzer M, Jansen M (2010) Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med 16(10):1141\u20131146. https:\/\/doi.org\/10.1038\/nm.2217","journal-title":"Nat Med"},{"issue":"2","key":"5389_CR59","first-page":"154","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au SK, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang PC (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non\u2013small-cell lung cancer of adenocarcinoma histology (PIONEER). JJoTO 9(2):154\u2013162","journal-title":"JJoTO"},{"issue":"5","key":"5389_CR60","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339\u2013346. https:\/\/doi.org\/10.1093\/jnci\/dji055","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"5389_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-81704-4","volume":"15","author":"JE Shin","year":"2025","unstructured":"Shin JE, Jung HA, Park S, Sun JM, Lee SH, Ahn JS, Ahn MJ, Shim BY (2025) Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer. Sci Rep 15(1):4593. https:\/\/doi.org\/10.1038\/s41598-024-81704-4","journal-title":"Sci Rep"},{"issue":"9","key":"5389_CR62","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/cns.14215","volume":"29","author":"Y Shu","year":"2023","unstructured":"Shu Y, Ding Y, Liu L, Zhang Q (2023) Cardiac adverse events associated with quetiapine: disproportionality analysis of FDA Adverse Event Reporting System. CNS Neurosci Ther 29(9):2705\u20132716. https:\/\/doi.org\/10.1111\/cns.14215","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"5389_CR63","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1159\/000430307","volume":"36","author":"Y Su","year":"2015","unstructured":"Su Y, Zhang H, Xu F, Kong J, Yu H, Qian B (2015) DNA repair gene polymorphisms in relation to non-small cell lung cancer survival. Cell Physiol Biochem 36(4):1419\u20131429. https:\/\/doi.org\/10.1159\/000430307","journal-title":"Cell Physiol Biochem"},{"key":"5389_CR64","doi-asserted-by":"publisher","unstructured":"Sugimoto T, Noguchi Y, Masuda R, Harada T, Toyama Y, Saguchi M, Yoshimura T (2025) Differences in safety signal detection between osimertinib and first- and second-generation EGFR-TKIs: a pharmacovigilance study using a spontaneous reporting system. Oncology pp 1\u201312.\u00a0https:\/\/doi.org\/10.1159\/000548593","DOI":"10.1159\/000548593"},{"issue":"2","key":"5389_CR65","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.lungcan.2015.08.004","volume":"90","author":"E Sugiyama","year":"2015","unstructured":"Sugiyama E, Umemura S, Nomura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Tsuboi M, Ohe Y, Goto K (2015) Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer 90(2):307\u2013313. https:\/\/doi.org\/10.1016\/j.lungcan.2015.08.004","journal-title":"Lung Cancer"},{"issue":"23","key":"5389_CR66","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.2217\/fon-2018-0535","volume":"15","author":"YL Sun","year":"2019","unstructured":"Sun YL (2019) Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. Future Oncol 15(23):2769\u20132777. https:\/\/doi.org\/10.2217\/fon-2018-0535","journal-title":"Future Oncol"},{"issue":"1","key":"5389_CR67","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40801-021-00268-1","volume":"9","author":"C Teng","year":"2022","unstructured":"Teng C, Frei CR (2022) Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drugs Real World Outcomes 9(1):23\u201329. https:\/\/doi.org\/10.1007\/s40801-021-00268-1","journal-title":"Drugs Real World Outcomes"},{"issue":"1","key":"5389_CR68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12929-025-01119-9","volume":"32","author":"C Tito","year":"2025","unstructured":"Tito C, Masciarelli S, Colotti G, Fazi F (2025) EGF receptor in organ development, tissue homeostasis and regeneration. J Biomed Sci 32(1):24. https:\/\/doi.org\/10.1186\/s12929-025-01119-9","journal-title":"J Biomed Sci"},{"issue":"27","key":"5389_CR69","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","volume":"34","author":"Y Urata","year":"2016","unstructured":"Urata Y, Katakami N, Morita S, Kaji R, Yoshioka H, Seto T, Satouchi M, Iwamoto Y, Kanehara M, Fujimoto D, Ikeda N, Murakami H, Daga H, Oguri T, Goto I, Imamura F, Sugawara S, Saka H, Nogami N, Negoro S, Nakagawa K, Nakanishi Y (2016) Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L. J Clin Oncol 34(27):3248\u20133257. https:\/\/doi.org\/10.1200\/JCO.2015.63.4154","journal-title":"J Clin Oncol"},{"issue":"1","key":"5389_CR70","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310. https:\/\/doi.org\/10.1002\/pds.668","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5389_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1702875","author":"Z Wen","year":"2025","unstructured":"Wen Z, Liu X, Yi Y, Lin G, Liu P, Zhang T (2025) The real-world safety profile of ranolazine: pharmacovigilance analysis of the FAERS database. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2025.1702875","journal-title":"Front Pharmacol"},{"issue":"11","key":"5389_CR72","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS (2017) Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol 18(11):1454\u20131466. https:\/\/doi.org\/10.1016\/S1470-2045(17)30608-3","journal-title":"Lancet Oncol"},{"issue":"8","key":"5389_CR73","doi-asserted-by":"publisher","first-page":"4057","DOI":"10.21037\/jtd-19-4000A","volume":"12","author":"X Xie","year":"2020","unstructured":"Xie X, Wang X, Wu S, Yang H, Liu J, Chen H, Ding Y, Ling L, Lin H (2020) Fatal toxic effects related to EGFR tyrosine kinase inhibitors based on 53 cohorts with 9,569 participants. J Thorac Dis 12(8):4057\u20134069. https:\/\/doi.org\/10.21037\/jtd-19-4000A","journal-title":"J Thorac Dis"},{"issue":"6","key":"5389_CR74","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1267\/ahc.19031","volume":"52","author":"Y Yamamoto","year":"2019","unstructured":"Yamamoto Y, Saita T, Oka A, Kataoka H, Shin M (2019a) Localization and Accumulation Studies of Dacomitinib in Rat Intestines and Skin by Immunohistochemistry. Acta Histochem Cytochem 52(6):101\u2013106. https:\/\/doi.org\/10.1267\/ahc.19031","journal-title":"Acta Histochem Cytochem"},{"issue":"6","key":"5389_CR75","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1267\/ahc.19031","volume":"52","author":"Y Yamamoto","year":"2019","unstructured":"Yamamoto Y, Saita T, Oka A, Kataoka H, Shin M (2019b) Localization and accumulation studies of dacomitinib in rat intestines and skin by immunohistochemistry. Acta Histochem Cytochem 52(6):101\u2013106. https:\/\/doi.org\/10.1267\/ahc.19031","journal-title":"Acta Histochem Cytochem"},{"key":"5389_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.573512","author":"B Yang","year":"2021","unstructured":"Yang B, Luo C, Yu M, Zhou L, Tao B, Tang B, Zhou Y, Zhu J, Huang M, Peng F, Liu Y, Xu Y, Zhang Y, Zhou X, Xue J, Li Y, Wang Y, Li Z, Lu Y, Lui S, Gong Y (2021) Changes of brain structure in patients with metastatic non-small cell lung cancer after long-term target therapy with EGFR-TKI. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2020.573512","journal-title":"Front Oncol"},{"issue":"3","key":"5389_CR77","first-page":"197","volume":"95","author":"J Yokota","year":"2010","unstructured":"Yokota J, Kohno T (2010) Molecular footprints of human lung cancer progression. JCS 95(3):197\u2013204","journal-title":"JCS"},{"issue":"1","key":"5389_CR78","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12885-023-11201-w","volume":"23","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Ding Y, Shu Y, Chen J (2023a) A real-world disproportionality analysis of rucaparib: post-marketing pharmacovigilance data. BMC Cancer 23(1):745. https:\/\/doi.org\/10.1186\/s12885-023-11201-w","journal-title":"BMC Cancer"},{"issue":"7","key":"5389_CR79","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14740338.2023.2193392","volume":"22","author":"J Zhang","year":"2023","unstructured":"Zhang J, Qiu T, Zhou SC, Chen E (2023b) Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event reporting system database. Expert Opin Drug Saf 22(7):849\u2013856. https:\/\/doi.org\/10.1080\/14740338.2023.2193392","journal-title":"Expert Opin Drug Saf"},{"key":"5389_CR80","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587","author":"YL Zhang","year":"2016","unstructured":"Zhang YL, Yuan JQ, Wang KF, Fu XH, Tang JL (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.12587","journal-title":"Oncotarget"},{"key":"5389_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103305","volume":"160","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Cheng B, Chen Z, Li J, Liang H, Chen Y, Zhu F, Li C, Xu K, Xiong S, Lu W, Chen Z, Zhong R, Zhao S, Xie Z, Liu J, Liang W, He J (2021) Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. Crit Rev Oncol Hematol 160:103305. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103305","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"5389_CR82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/14740338.2020.1753697","volume":"19","author":"JY Zhou","year":"2020","unstructured":"Zhou JY, Liu SY, Wu YL (2020) Safety of EGFR-TKIs for EGFR mutation-positive non-small cell lung cancer. Expert Opin Drug Saf 19(5):589\u2013599. https:\/\/doi.org\/10.1080\/14740338.2020.1753697","journal-title":"Expert Opin Drug Saf"},{"issue":"13","key":"5389_CR83","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2217\/fon-2018-0944","volume":"15","author":"Q Zhou","year":"2019","unstructured":"Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, Wang T, Sandin R, Noonan K, Gernhardt D, Mok TS (2019) Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncol 15(13):1481\u20131491. https:\/\/doi.org\/10.2217\/fon-2018-0944","journal-title":"Future Oncol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05389-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05389-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05389-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T03:01:04Z","timestamp":1784775664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05389-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["5389"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05389-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval and consent were not required as this study was based on publicly available data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}